Rivaroxaban Tablets (Xarelto)

Elliott, William T.; Chan, James
August 2011
Internal Medicine Alert;8/15/2011, Vol. 33 Issue 15, p117
The article offers information on the drug for the treatment of deep vein thrombosis (DVT), Rivaroxaban, which was developed by Bayer in the U.S.


Related Articles

  • Home treatment for deep-vein thrombosis is safe and effective.  // Modern Medicine;Jul96, Vol. 64 Issue 7, p60 

    Presents an abstract on articles about the safety of deep-vein thrombosis home treatments by M. Levine, M.M.W. Koopman et al published in the March 14, 1996 issue of the `New England Journal of Medicine'.

  • Antithrombotic agent.  // Geriatrics;June97, Vol. 52 Issue 6, p21 

    Focuses on danaparoid sodium (Orgaran) injection for prevention of postoperative deep vein thrombosis (DVT) in patients undergoing elective hip replacement surgery. Recommended dosage of the agent; Most common adverse reactions of the agent.

  • Using published, institutional data to evaluate the cost effectiveness of DVT prophylaxis. Wade, William E.; Taylor, A. Thomas // Formulary;Dec96, Vol. 31 Issue 12, p1203 

    Reviews the pharmacologic therapies for deep vein thrombosis (DVT) prophylaxis in patients undergoing major orthopedic surgery. Prevention of DVT; Use of low molecular weight herpins; Administering the drug to total hip replacement and knee replacement surgery patients. INSET: Treatment of DVT..

  • Thinner is better? Schwade, Steve // Prevention;Sep96, Vol. 48 Issue 9, p51 

    Examines deepvein thrombosis (DVT). Disorder that forms blood clots in the legs of people with DVT; Suggestion that a drug called low-molecular-weight heparin (LMWH) can help people with DVT treat themselves; Results of a study of people who used LMWH.

  • Outpatient low-molecular-weight heparin vs. in-hospital heparin for proximal DVT. Simonelli, Paul F. // Cortlandt Forum;11/25/97, Vol. 10 Issue 11, p38 

    Examines the results of a study supporting the evolving practice of limited in-hospital treatment of proximal lower-extremity deep vein thrombosis. Comparison of the treatment mode with standard continuous intravenous heparin; Impact of hospital stay; Rate of symptomatic recurrence.

  • Management of deep-vein thrombosis. Francis, Charles W.; Kerr, Colin P. // JAMA: Journal of the American Medical Association;2/16/94, Vol. 271 Issue 7, p556 

    Answers questions on the management of deep-vein thrombosis. Lack of clinical studies on return to ambulation and normal activity after treatment; Response to bed rest and anticoagulant therapy; Years to develop chronic venous insufficiency.

  • Patient preference & treatment decisions. Levin, Arthur Aaron // HealthFacts;Aug94, Vol. 19 Issue 183, p2 

    Discusses patient preference in an effort to resolve uncertainty about the best drug treatment for deep-vein thrombosis (DVT). Description of DVT; Uncertainty on using heparin alone in treating DVT or adding thrombolytic to the medication; Review of studies of DVT drug treatment by Doctor James...

  • Breaking out of the silo:One health system's experience. Vichiendilokkul, Anna // American Journal of Health-System Pharmacy;10/15/2002, Vol. 59 Issue 20, pS15 

    Pharmacoeconomic evidence for inpatient deep vein thrombosis (DVT) treatment with low-molecular-weight heparins (LMWHs) and one health system's experience with this treatment compared with unfractionated heparins (UFHs) are examined, Applying clinical and pharmacoeconomic evidence to clinical...

  • DVT treatment at home: Low-molecular-weight heparin is safe, effective.  // Geriatrics;Jul96, Vol. 51 Issue 7, p61 

    Focuses on two studies suggesting that patients with acute proximal thrombosis often can be treated safely at home with subcutaneously administered low-molecular-weight heparin. Comparison with standard-in-hospital intravenous heparin.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics